Neurocrine delivered a strong Q3 2025 with 28% revenue growth year-over-year. INGREZZA achieved record sales, while CRENESSITY posted impressive early adoption figures. Operating income and profitability also improved significantly.

Neurocrine delivered $682 million in net product sales in Q2 2025, driven by INGREZZA’s record prescription growth and strong early adoption of CRENESSITY, with solid profitability and increased R&D investment.

Neurocrine Biosciences posted $572.6M in revenue and a GAAP net income of $7.9M in Q1 2025. INGREZZA saw strong demand while CRENESSITY had a successful market entry. Operating income declined due to higher R&D and SG&A spending to support clinical programs and launches.

Neurocrine Biosciences reported strong Q4 2024 results with total revenue of $627.7 million, driven by INGREZZA sales growth of 23%. The company saw increased R&D and SG&A expenses related to pipeline expansion and new product launches.

Neurocrine Biosciences reported strong third-quarter 2024 results, driven by a 26% year-over-year increase in INGREZZA sales, reaching $613 million. The company has raised its 2024 INGREZZA sales guidance to $2.30 - $2.32 billion and the Board authorized a $300 million share repurchase plan.

Neurocrine Biosciences reported strong second-quarter results, with INGREZZA net product sales reaching $580 million, a 32% increase year-over-year. The company raised its 2024 INGREZZA net product sales guidance to $2.25 - $2.3 billion.

Neurocrine Biosciences announced its Q1 2024 financial results, highlighted by INGREZZA's net product sales of $506 million, a 23% increase year-over-year. The company also submitted New Drug Applications for crinecerfont and reported positive Phase 2 results for NBI-1065845.

Neurocrine Biosciences reported Q4 2023 net product sales of $507.2 million and net income of $147.7 million. INGREZZA net product sales grew 25% compared to Q4 2022, reaching $500 million. The company provided full year 2024 INGREZZA net product sales guidance of $2.1 - $2.2 billion.

Neurocrine Biosciences reported strong Q3 2023 results, driven by a 29% year-over-year growth in INGREZZA sales, which reached $486 million. The company also raised its full-year sales guidance for INGREZZA to $1.82 - $1.84 billion. Positive Phase 3 results were announced for Crinecerfont in congenital adrenal hyperplasia.

Neurocrine Biosciences announced positive financial results for the second quarter ended June 30, 2023. INGREZZA's performance enabled the company to raise its net sales guidance for 2023, with a strong operational setup for the second half of the year.

Neurocrine Biosciences reported a GAAP net loss of $77 million, or $0.79 per share, and a non-GAAP net loss of $50 million, or $0.51 per share. INGREZZA's first quarter net product sales reached $410 million, a 36% increase compared to the first quarter of 2022. The company reiterated its full-year INGREZZA net product sales guidance of $1.67 to $1.77 billion.

Neurocrine Biosciences reported Q4 2022 net product sales of $404.6 million and GAAP net income of $89 million, with diluted earnings per share of $0.88. INGREZZA net product sales were $399 million, reflecting a 33% growth compared to Q4 2021. The company completed enrollment in adult and pediatric registrational studies of crinecerfont for congenital adrenal hyperplasia and anticipates top-line data in the second half of 2023.

Neurocrine Biosciences reported strong Q3 2022 financial results, with INGREZZA net product sales reaching $376 million, a 31% increase compared to Q3 2021. The company also raised its full-year 2022 INGREZZA sales guidance to $1.4 - $1.425 billion. GAAP net income for the quarter was $69 million, or $0.69 per share, compared to $23 million, or $0.23 per share, in Q3 2021.

Neurocrine Biosciences announced its financial results for the second quarter ended June 30, 2022, and raised net sales guidance for INGREZZA in 2022. INGREZZA's strong performance in the first half of the year drove the increased full-year net sales guidance.

Neurocrine Biosciences reported first quarter net product sales of $303 million for INGREZZA. The company's GAAP net income was $14 million, or $0.14 per share, and non-GAAP net income was $30 million, or $0.30 per share.

Neurocrine Biosciences reported Q4 2021 net product sales of $303.5 million, a GAAP net loss of $7.3 million, and a non-GAAP net income of $4.3 million. The company's INGREZZA net product sales reached $1.1 billion for fiscal year 2021. They also provided financial guidance for 2022, including INGREZZA net product sales guidance of $1.25 - $1.35 billion.

Neurocrine Biosciences announced positive financial results for the third quarter of 2021, with INGREZZA's continued growth driving revenue. The company is expanding its commercial footprint and investing in its R&D pipeline, with several clinical data read-outs expected over the next two years.

Neurocrine Biosciences reported second quarter 2021 financial results, highlighting sustained growth for INGREZZA with net product sales of $265 million and approximately 48,900 total prescriptions. The company is also advancing its R&D pipeline with 9 mid-to-late-stage clinical trials planned for this year.

Neurocrine Biosciences reported first quarter INGREZZA net product sales of $230 million. The company is focused on restoring INGREZZA growth as the impact of the pandemic wanes and is executing its plan to build a leading neuroscience-based company.

Neurocrine Biosciences announced its Q4 and full-year 2020 financial results, highlighting a non-cash tax benefit of $296 million. INGREZZA net product sales for the fourth quarter were $240 million. The company is planning to initiate eight mid-to-late stage clinical studies in 2021.

Neurocrine Biosciences announced its Q3 2020 financial results, with INGREZZA net product sales reaching $254 million, a 28% increase year-over-year. The company reported a GAAP net loss of $58 million, or $0.62 per share, and a non-GAAP net income of $96 million, or $0.97 per share. ONGENTYS was launched in the U.S. in late September.

Neurocrine Biosciences reported strong first quarter 2020 results with INGREZZA net product sales of $231 million, representing a 69% year-over-year increase. The FDA approved ONGENTYS for Parkinson's disease, triggering a $20 million milestone. The company is in a strong financial position with over $1 billion in cash, cash equivalents and debt securities available-for-sale.

Neurocrine Biosciences reported a strong Q4 2019, with INGREZZA net product sales reaching $238 million. The company's net income was $34 million, and it ended the year with $970 million in cash and marketable securities. Increased investment in R&D and SG&A is expected for 2020, driven by pipeline expansion and the anticipated launch of opicapone.